Nov 14, 2023 / 10:00AM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
Thanks for joining us. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies. I'd like to welcome Yvonne Greenstreet, the CEO of Alnylam. Thanks so much for joining us today, Yvonne.
Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. - CEO & Director
It's a real pleasure to be here and glad to see such a full room. Wonderful. Is my microphone working? Yes.
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. So for those who may be new to the story, maybe give a 1-minute intro to Alnylam and some of the key catalysts coming up in the next 12 to 18 months.
Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. - CEO & Director
Absolutely. So Alnylam is -- some of you may know, is the leading RNAi company, and we're particularly proud of the fact that we brought to market 4 RNAi therapeutics, actually,
Alnylam Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers